Oral Anticoagulation in Hemodialysis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.
Also called NCT03799822
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 132 participants
- Sponsor
- Registry
-
NCT03799822
-
- Other papers using this trial's data
- Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium
- Registry status
- Completed
Technical summary
Registry record NCT03799822. Randomized; no masking; primary purpose prevention. Start 2017-05-01 (actual); primary completion 2020-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Oral Anticoagulation in Hemodialysis
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Rivaroxaban 10 MG Oral Tablet
- Intervention (Dietary supplement)
- MK-7 2000µg thrice weekly
- Intervention (Drug)
- Vitamin K Antagonist - Drug
- Lead sponsor
- Onze Lieve Vrouw Hospital
Record details
- Record id
cardio:ct-nct03799822- Content hash
aef77e121933188f92e793aee6371c0529f7472003f98c0cb427937db31e80bf